Hengrui Pharma(600276.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Hengrui Pharma
600276.SH
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
2.798 T
600276.SHMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking3/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE14.68%A
    • Profit Margin24.93%A
    • Gross Margin86.60%A
  • Growth ScoreB
    • Revenue YoY11.55%B
    • Net Profit YoY18.67%B
    • Total Assets YoY38.99%A
    • Net Assets YoY34.91%A
  • Cash ScoreB
    • Cash Flow Margin141.23%B
    • OCF YoY11.55%B
  • Operating ScoreC
    • Turnover0.53C
  • Debt ScoreA
    • Gearing Ratio10.02%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    M Stanley: HENGRUI PHARMA Forms USD15.2B Strategic Partnership with Bristol-Myers Squibb Company to Accelerate Globalization

    AASTOCKS News·
    SH
    600276
    -1.60%
    US
    BMY
    +0.54%
    SH
    588130
    +0.68%
    AASTOCKS News·
    SH
    600276
    -1.60%
    US
    BMY
    +0.54%
    SH
    588130
    +0.68%

    China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

    SCMP·
    US
    BMY
    +0.54%
    HK
    01276
    -2.69%
    US
    PILL
    -5.60%
    SCMP·
    US
    BMY
    +0.54%
    HK
    01276
    -2.69%
    US
    PILL
    -5.60%

    <![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>

    Pharmexec·
    SH
    600276
    -1.60%
    US
    BMY
    +0.54%
    US
    SBIO
    -3.43%
    Pharmexec·
    SH
    600276
    -1.60%
    US
    BMY
    +0.54%
    US
    SBIO
    -3.43%

    BMS and Hengrui forge $15.2bn alliance for early-stage drugs

    Pharmaceutical Technology·
    SH
    600276
    -1.60%
    US
    BMY
    +0.54%
    HK
    01276
    -2.69%
    Pharmaceutical Technology·
    SH
    600276
    -1.60%
    US
    BMY
    +0.54%
    HK
    01276
    -2.69%

    China’s Hengrui Jumps After Inking USD15 Billion Innovative Drug Deal With BMS

    Yicai·
    HK
    01276
    -2.69%
    SH
    600276
    -1.60%
    SH
    520880
    0.00%
    Yicai·
    HK
    01276
    -2.69%
    SH
    600276
    -1.60%
    SH
    520880
    0.00%
    © 2026 Longbridge｜Disclaimer